# Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

> **NCT06437678** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Liposomal Irinotecan Hydrochloride

## Key facts

- **NCT ID:** NCT06437678
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2025-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06437678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06437678, "Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06437678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*